108,087 Shares in Stoke Therapeutics, Inc. $STOK Bought by Nuveen LLC

Nuveen LLC acquired a new stake in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 108,087 shares of the company's stock, valued at approximately $719,000. Nuveen LLC owned about 0.20% of Stoke Therapeutics at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of STOK. Wells Fargo & Company MN increased its stake in shares of Stoke Therapeutics by 51.2% during the 4th quarter. Wells Fargo & Company MN now owns 16,786 shares of the company's stock valued at $185,000 after acquiring an additional 5,682 shares during the last quarter. Invesco Ltd. acquired a new position in shares of Stoke Therapeutics during the 4th quarter valued at about $133,000. Dimensional Fund Advisors LP increased its stake in shares of Stoke Therapeutics by 103.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 538,900 shares of the company's stock valued at $5,943,000 after acquiring an additional 273,890 shares during the last quarter. Tower Research Capital LLC TRC increased its stake in shares of Stoke Therapeutics by 70.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 11,930 shares of the company's stock valued at $132,000 after acquiring an additional 4,918 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its stake in shares of Stoke Therapeutics by 6.3% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 37,455 shares of the company's stock valued at $414,000 after acquiring an additional 2,215 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the stock. Cantor Fitzgerald raised shares of Stoke Therapeutics to a "strong-buy" rating in a research note on Wednesday, May 14th. HC Wainwright dropped their target price on shares of Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating for the company in a research report on Wednesday, May 14th. Jefferies Financial Group started coverage on shares of Stoke Therapeutics in a research report on Friday, July 18th. They set a "buy" rating and a $30.00 target price for the company. Chardan Capital reissued a "buy" rating and set a $24.00 target price on shares of Stoke Therapeutics in a research report on Wednesday, August 13th. Finally, Needham & Company LLC reissued a "buy" rating and set a $22.00 target price on shares of Stoke Therapeutics in a research report on Tuesday, July 1st. Two analysts have rated the stock with a Strong Buy rating and seven have given a Buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $25.57.

Stoke Therapeutics Price Performance

NASDAQ STOK traded up $1.05 on Friday, reaching $20.68. The company had a trading volume of 542,954 shares, compared to its average volume of 999,282. The firm has a market capitalization of $1.13 billion, a PE ratio of 24.33 and a beta of 1.14. Stoke Therapeutics, Inc. has a 1 year low of $5.35 and a 1 year high of $20.90. The firm has a 50-day moving average of $14.92 and a 200-day moving average of $11.06.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.40) earnings per share for the quarter, topping analysts' consensus estimates of ($0.57) by $0.17. The firm had revenue of $13.82 million during the quarter, compared to analysts' expectations of $31.51 million. Stoke Therapeutics had a return on equity of 18.32% and a net margin of 26.25%. As a group, sell-side analysts expect that Stoke Therapeutics, Inc. will post -2.01 EPS for the current fiscal year.

Insider Activity

In other news, General Counsel Jonathan Allan sold 14,922 shares of the stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $20.14, for a total transaction of $300,529.08. Following the completion of the transaction, the general counsel directly owned 18,176 shares in the company, valued at approximately $366,064.64. This represents a 45.08% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Barry Ticho sold 5,501 shares of the stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $19.87, for a total value of $109,304.87. Following the transaction, the insider owned 18,469 shares of the company's stock, valued at approximately $366,979.03. This trade represents a 22.95% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 107,719 shares of company stock worth $2,063,359. 9.50% of the stock is currently owned by insiders.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.